The in vitro susceptibility of five strains of varicella-zoster virus to acyclovir was examined by the plaque-reduction method in human diploid lung cells. The 50% effective doses of acyclovir ranged from 2.06 ,LM to 6.28 ,uM in a 7-day assay, with a mean of 3.65 tiM. Irreversible inhibition of plaque formtation was achieved by drug doses exceeding the 50% effective dose for plaque reduction but nontoxic to the cells. Studies on the relative in vitro susceptibility of varicella-zoster virus and herpes simplex virus types 1 and 2 to acyclovir suggested that varicella-zoster virus is two-to eightfold less susceptible to the drug. The antiviral potency of acyclovir for varicella-zoster virus in vitro was compared with that of several other nucleoside analogs. Analysis of the metabolism of acyclovir in varicellazoster virus-infected WI-38 cells revealed that, as with herpes simplex virus types 1 and 2, the formation of the triphosphate forms of the drug is specific to viral infection.
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Varicella-zoster virus (VZV) is a member of the herpes group which shares several biological features with the well-characterized herpes simplex virus (HSV). These include the ability to establish latency during the primary infection, and subsequently to reactivate despite the presence of circulating antibody (1, 17) . Primary varicella infection (chicken pox) in normal nonimmune individuals is generally a self-resolving, uncomplicated disease. Natural resolution of either the primary infection or reactivated virus infection (herpes zoster) is more difficult, however, in immunocompromised hosts (19, 26) . There is a need for antiviral therapy which would ameliorate the clinical course of infection in this patient population and prevent the systemic complications resulting from disseminated disease.
Cytosine arabinoside and idoxuridine have been found unsatisfactory for the systemic treatment of varicella zoster in these patients due to toxicity (3, 8, 25) . Controlled studies with adenine arabinoside (ara-A) have indicated potential usefulness in the treatment of both localized and disseminated disease (16, 27) . Due to low solubility of the drug and its deamination in vivo, systemic administration of ara-A requires continuous intravenous infusion of the hospitalized patient.
The nucleoside analog 9-(2-hydroxyethoxymethyl)guanine (acyclovir, previously referred to as acycloguanosine) has been shown to be an effective and specific antiviral agent against HSV types 1 and 2 both in vitro and in vivo (2, 4, 6, 7, 11, 12, 18, (22) (23) (24) . This antiherpetic agent has demonstrated low toxicity, good metabolic stability, and broad tissue distribution in preclinical trials (9, 24) . Therefore, acyclovir can be considered an antiviral agent with great therapeutic potential in humans.
This report describes the in vitro susceptibility of VZV to acyclovir, and compares this sensitivity with that of HSV type 1 (HSV-1) and 2. The antiviral potency of acyclovir against VZV in vitro is compared with that of the antiherpetic compounds idoxuridine, cytosine arabinoside, and ara-A. Finally, preliminary studies of the metabolism of acyclovir in VZV-infected cells are presented.
( There was a lag time for resumption of plaque formation after drug removal which also correlated with both drug concentration and length of treatment. The relative susceptibility of VZV and HSV-1 and 2 to acyclovir was examined in WI-38 and HEK cells by the plaque-reduction assay. Time was allowed for maximum plaque development: 3 days in the case of HSV infections, and 7 days for VZV infections. The average ED50 of acyclovir was 0.59 ,uM for HSV-1 (strains KOS and H29) in WI-38 cells and 0.91 AM for HSV-2 (strains MS and 333). The susceptibility of HSV to inhibition by acyclovir has been shown to vary with host cell species (6, 11); EDso's of 0.1 to 0.3 ,uM have been measured for several strains of HSV-1 in Vero cells (11, 13) , comparative plaque-reduction assays in HEK cells have yielded average ED50's of 0.72 ,uM for strain H29 and 0.74 itM for strain MS, whereas the CaQu and Diaz strains of VZV require drug concentrations of 4.14 and 5.24 ,uM, respectively (Fig. 3) . Results of these studies suggest that VZV is 2-to 8-fold less susceptible to acyclovir than HSV-1 or 2 in these human cells.
The antiviral activity of several antiherpetic compounds was measured against VZV strains Ellen and CaQu in a 7-day plaque-reduction assay (Fig. 4) . Cytosine arabinoside and idoxuridine were most active in these assays. The antiviral potencies of ara-A and acyclovir, while slightly lower, were comparable. The addition of an inhibitor of adenosine deaminase did not enhance the activity of ara-A in this cell line (4 shown). The antiviral activity of acyclovir has been associated with anabolism of the nucleoside to the triphosphate form in HSV-infected cells (11, 24) . VZV-infected WI-38 cells were treated with '4C-labeled acyclovir for 16 h, harvested, extracted, and analyzed by high-pressure liquid chromatography. Examination of the elution profiles revealed the presence of acyclovir triphosphate in VZV-infected cells. Phosphorylation of the drug occurred specifically in virusinfected cells (Fig. 5) . Furthermore, infected WI-38 cells contained higher levels of unconverted nucleoside than did uninfected cells. DISCUSSION The in vitro susceptibility of HSV to acyclovir requires the expression of both the viral thymidine kinase and viral deoxyribonucleic acid polymerase (11) . The drug is converted to the monophosphate form by the viral thymidine kinase and subsequently to the di-and triphosphate forms by host enzymes (14) . The triphosphate form of acyclovir is a competitive inhibitor of the virus-induced deoxyribonucleic acid polymerase (11, 13 (Table 3) .
The demonstrated efficacy of acyclovir for VZV infections in vitro suggest that this antiviral agent may be useful in the treatment of patients with varicella-zoster infections.
